Benzyl 1-[[4-(trifluoromethoxy)benzoyl]amino]cyclohexane-1-carboxylate | 896740-96-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Benzyl 1-[[4-(trifluoromethoxy)benzoyl]amino]cyclohexane-1-carboxylate
• CAS: 896740-96-8
• 化学式: C₂₂H₂₂F₃NO₄
• 分子量: 421.416
• InChiKey: AXDRIRVLMBQKFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  Benzyl 1-[[4-(trifluoromethoxy)benzoyl]amino]cyclohexane-1-carboxylate 在 钯 氢气 作用下， 以 乙醇 为溶剂， 生成 1-[[4-(Trifluoromethoxy)benzoyl]amino]cyclohexane-1-carboxylic acid
  参考文献：
  名称：

  Keto-1,3,4-oxadiazoles as cathepsin K inhibitors

  摘要：

  We have prepared a series of cathepsin K inhibitors bearing the keto-1,3,4-oxadiazole warhead capable of forming a hemithioketal complex with the target enzyme. By modifying binding moieties at the P-1, P-2, and prime side positions of the inhibitors, we have achieved selectivity over cathepsins B, L, and S, and have achieved sub-nanomolar potency against cathepsin K. This series thus represents a promising chemotype that could be used in diseases implicated by imbalances in cathepsin K activity such as osteoporosis. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.03.001
• 作为产物：
  描述：

  Benzyl 1-aminocyclohexane-1-carboxylate;hydrochloride 、 4-三氟甲氧基苯甲酸 在 二乙基异丙基胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 Benzyl 1-[[4-(trifluoromethoxy)benzoyl]amino]cyclohexane-1-carboxylate
  参考文献：
  名称：

  Keto-1,3,4-oxadiazoles as cathepsin K inhibitors

  摘要：

  We have prepared a series of cathepsin K inhibitors bearing the keto-1,3,4-oxadiazole warhead capable of forming a hemithioketal complex with the target enzyme. By modifying binding moieties at the P-1, P-2, and prime side positions of the inhibitors, we have achieved selectivity over cathepsins B, L, and S, and have achieved sub-nanomolar potency against cathepsin K. This series thus represents a promising chemotype that could be used in diseases implicated by imbalances in cathepsin K activity such as osteoporosis. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.03.001

文献信息

• [EN] CYSTEINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE LA CYSTEINE PROTEASE
  申请人：AXYS PHARM INC

  公开号：WO2002023784A2

  公开（公告）日：2002-03-21

  The present invention relates to compounds, compositions and methods for treating diseases associated with cysteine protease activity, particularly diseases associated with activity of cathepsins B, K, L or S.The present invention thus provides compounds of Formula (I): pharmaceutical compositions comprising compounds of Formula (I) and methods of treating diseases associated with cysteine protease activity using pharmaceutical compositions comprising compounds of Formula (I).
• Keto-1,3,4-oxadiazoles as cathepsin K inhibitors
  作者：James T. Palmer、Bernard L. Hirschbein、Harry Cheung、John McCarter、James W. Janc、Z. Walter Yu、Gregg Wesolowski

  DOI：10.1016/j.bmcl.2006.03.001

  日期：2006.6

  We have prepared a series of cathepsin K inhibitors bearing the keto-1,3,4-oxadiazole warhead capable of forming a hemithioketal complex with the target enzyme. By modifying binding moieties at the P-1, P-2, and prime side positions of the inhibitors, we have achieved selectivity over cathepsins B, L, and S, and have achieved sub-nanomolar potency against cathepsin K. This series thus represents a promising chemotype that could be used in diseases implicated by imbalances in cathepsin K activity such as osteoporosis. (c) 2006 Elsevier Ltd. All rights reserved.